Poxel SA
- Country
- 🇫🇷France
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.poxelpharma.com
Clinical Trials
16
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 16
- Registration Number
- NCT05441904
- Locations
- 🇬🇧
HMR, London, Nw10, United Kingdom
Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 12
- Registration Number
- NCT05200104
Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 24
- Registration Number
- NCT05146284
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 117
- Registration Number
- NCT04321343
- Locations
- 🇺🇸
Study site 11, Chandler, Arizona, United States
🇺🇸Study site 12, Glendale, Arizona, United States
🇺🇸Study site 13, Tucson, Arizona, United States
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 17
- Registration Number
- NCT03950882
- Locations
- 🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
- Prev
- 1
- 2
- 3
- Next
News
Poxel Enters Reorganization Proceedings as Clinical-Stage Biotech Faces Financial Restructuring
Poxel SA, a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, has entered judicial reorganization proceedings following a court hearing on August 5, 2025.
Poxel's PXL065 Shows Promise in Preclinical Hypertrophic Cardiomyopathy Study, Data to be Presented at ESC 2025
Poxel's PXL065, a deuterium-stabilized R-enantiomer of pioglitazone, demonstrated significant benefits in preventing pathological myocardial remodeling in a mouse model of hypertrophic cardiomyopathy.
Robust Pipeline of 80+ Therapies Advancing for Chronic Kidney Disease Treatment in 2025
DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern.
Adrenoleukodystrophy: Emerging Therapies Show Promise in Clinical Trials
Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system.